Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Non-Current Assets (2016 - 2025)

Vanda Pharmaceuticals' Non-Current Assets history spans 16 years, with the latest figure at $141.7 million for Q4 2025.

  • On a quarterly basis, Non-Current Assets fell 34.8% to $141.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $829.2 million, a 3.08% decrease, with the full-year FY2025 number at $141.7 million, down 34.8% from a year prior.
  • Non-Current Assets hit $141.7 million in Q4 2025 for Vanda Pharmaceuticals, down from $233.6 million in the prior quarter.
  • Over the last five years, Non-Current Assets for VNDA hit a ceiling of $233.6 million in Q3 2025 and a floor of $105.0 million in Q3 2023.
  • Historically, Non-Current Assets has averaged $157.7 million across 5 years, with a median of $121.5 million in 2021.
  • Biggest five-year swings in Non-Current Assets: skyrocketed 102.53% in 2024 and later tumbled 34.8% in 2025.
  • Tracing VNDA's Non-Current Assets over 5 years: stood at $115.5 million in 2021, then decreased by 0.46% to $115.0 million in 2022, then surged by 87.46% to $215.5 million in 2023, then rose by 0.84% to $217.3 million in 2024, then tumbled by 34.8% to $141.7 million in 2025.
  • Business Quant data shows Non-Current Assets for VNDA at $141.7 million in Q4 2025, $233.6 million in Q3 2025, and $229.8 million in Q2 2025.